DRS was the chairman of the ABC Faculty and is a member of the ABC-Trauma Faculty, which are selleck inhibitor both managed by Physicians World Europe GmbH, Mannheim, Germany and sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland and CSL Behring GmbH, Marburg, Germany. In the past 5 years, DRS has received honoraria or travel support for consulting or lecturing from the following companies: Abbott AG, Baar, Switzerland, AMGEN GmbH, Munich, Germany, AstraZeneca AG, Zug, Switzerland, Bayer (Schweiz) AG, Z��rich, Switzerland, Baxter AG, Volketswil, Switzerland, Baxter S.p.A., Roma, Italy, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Curacyte AG, Munich, Germany, Ethicon Biosurgery, Sommerville, NJ, USA, Fresenius SE, Bad Homburg v.

d.H., Germany, Galenica AG, Bern, Switzerland (including Vifor SA, Villars-sur-Glane, Switzerland), GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany, Janssen-Cilag AG, Baar, Switzerland, Janssen-Cilag EMEA, Beerse, Belgium, Merck Sharp & Dohme-Chibret AG, Opfikon-Glattbrugg, Switzerland, Novo Nordisk A/S, Bagsv?rd, Denmark, Octapharma AG, Lachen, Switzerland, Organon AG, Pf?ffikon/SZ, Switzerland, Oxygen Biotherapeutics, Costa Mesa, CA, Pentapharm GmbH (now tem Innovations GmbH), Munich, Germany, ratiopharm Arzneimittel Vertriebs-GmbH, Vienna, Austria, Roche Pharma (Schweiz) AG, Reinach, Switzerland, Schering-Plough International, Inc.

, Kenilworth, NJ, USA, Vifor Pharma Deutschland GmbH, Munich, Germany, Vifor Pharma ?sterreich GmbH, Vienna, Austria, and Vifor (International) AG, St Gallen, Switzerland.AcknowledgementsSupport and manuscript preparation was provided by Physicians World Europe GmbH (Mannheim, Germany) supported by an unrestricted grant from CSL Behring GmbH (Marburg, Germany).
In recent years, our knowledge of the characteristics of patients who are admitted to critical care with sepsis, severe sepsis, or septic shock has greatly advanced thanks to the findings of numerous observational studies [1-6]. There is wide Entinostat variation in the incidence of sepsis and severe sepsis in the intensive care unit (ICU) setting, with reported rates ranging from 20% to 80%, and reported mortality of 20% to 50% [1-6]. Septic shock, defined as a state of acute circulatory failure characterized by persistent hypotension unexplained by other causes, despite adequate fluid resuscitation [7], affects between 10% and 30% of patients managed in the ICU [1,3,4,8-10], and its incidence is increasing [3].